Expression of small extracellular chondroitin/dermatan sulfate proteoglycans is differentially regulated in human endothelial cells.
We have examined the expression of the small extracellular chondroitin/dermatan sulfate proteoglycans (CS/DS PGs), biglycan, decorin, and PG-100, which is the proteoglycan form of colony stimulating factor-1, in the human endothelial cell line EA.hy 926. We have also examined whether modulation of the phenotype of EA.hy 926 cells by tumor necrosis factor-alpha (TNF-alpha) is associated with specific changes in the synthesis of these PGs. We demonstrate that EA.hy 926 cells, when they form monolayer cultures typical of macrovascular endothelial cells, express and synthesize detectable amounts of biglycan and PG-100, but not decorin. On SDS-polyacrylamide gel electrophoresis both PGs behave like proteins of the relative molecular weight of approximately 250,000. TNF-alpha that changed the morphology of the cells from a polygonal shape into a spindle shape and that also stimulated the detachment of the cells from culture dish, markedly decreased the net synthesis of biglycan, whereas the net synthesis of PG-100 was increased. These changes were parallel with those observed at the mRNA level of the corresponding PGs. The proportions of the different sulfated CS/DS disaccharide units of PGs were not affected by TNF-alpha. Several other growth factors/cytokines, such as interferon-gamma, fibroblast growth factors-2 (FGF-2) and -7 (FGF-7), interleukin-1beta, and transforming growth factor-beta, unlike TNF-alpha, modulated neither the morphology nor the biglycan expression of EA.hy 926 cells under the conditions used in the experiments. However, PG-100 expression was increased also in response to FGF-2 and -7 and transforming growth factor-beta. None of the above cytokines, including TNF-alpha, was able to induce decorin expression in the cells. Our results indicate that the regulatory elements controlling the expression of the small extracellular CS/DS PGs in human endothelial cells are different.
Nelimarkka
L
L
Department of Medical Biochemistry, FIN-20520 Turku, Finland.
Kainulainen
V
V
Schönherr
E
E
Moisander
S
S
Jortikka
M
M
Lammi
M
M
Elenius
K
K
Jalkanen
M
M
Järveläinen
H
H
D058578:Biglycan; D015153:Blotting, Western; D048429:Cell Size / Q000187:drug effects; D002478:Cells, Cultured; D002809:Chondroitin Sulfates / Q000378:metabolism*; D016207:Cytokines / Q000494:pharmacology; D058575:Decorin; D003871:Dermatan Sulfate / Q000378:metabolism*; D004727:Endothelium / Q000378:metabolism; D005109:Extracellular Matrix / Q000378:metabolism; D016326:Extracellular Matrix Proteins; D006801:Humans; D016173:Macrophage Colony-Stimulating Factor / Q000378:metabolism; D008970:Molecular Weight; D011509:Proteoglycans / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology
C546884:BGN protein, human; D058578:Biglycan; D016207:Cytokines; C546878:DCN protein, human; D058575:Decorin; D016326:Extracellular Matrix Proteins; D011509:Proteoglycans; D014409:Tumor Necrosis Factor-alpha; D003871:Dermatan Sulfate; D016173:Macrophage Colony-Stimulating Factor; D002809:Chondroitin Sulfates